News

Emergent has announced that BioThrax (Anthrax Vaccine Adsorbed) has been granted a shelf life extension from 3 to 4 years by the FDA. Based on the approval, Emergent

California-based Orexigen has announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK), that expands the company’s IP position underlying Contrave, its lead product candidate for the

GTx has declared results of a Phase II clinical trial evaluating Ostarine, an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known

Human Genome Sciences has announced the positive long-term Phase-II trial data for Benlysta (belimumab, formerly LymphoStat-B) in patients with active systemic lupus erythematosus. Benlysta is a human monoclonal

Sanofi-Aventis and Regeneron have announced that advanced ovarian cancer patients with recurrent symptomatic malignant ascites (SMA) receiving aflibercept (VEGF Trap) in a randomized, placebo-controlled Phase 2 study, experienced

Regeneron has signed two royalty agreements with Novartis that replaces previous collaboration and license agreement. Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide

For the quarter, the Company announced adjusted earnings per share of $0.03, compared with $0.08 in the corresponding period a year ago. Quarterly Highlights — Net revenue of

Xenon has announced a strategic alliance with Merck through an affiliate, to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease. In collaboration

Neurim has declared the preliminary results of phase-III study of Circadin 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. Circadinis, a